Onconova Therapeutics Story Overview

ONTX -- USA Stock  

USD 0.47  0.0194  3.96%

Macroaxis does not monitor all media channels or aggregates social signals for Onconova Therapeutics. But even though we do not provide professional-grade financial sentiment analysis on Onconova Therapeutics, we do publish noise-free headlines that can be used to derive useful patterns or even a trading strategy for Onconova Therapeutics. Additionally take a look at Onconova Therapeutics Hype Analysis, Onconova Therapeutics Correlation and Onconova Therapeutics Performance.
Conversion by Michael Hoffman of 140449 shares of Onconova Therapeutics
Filed transaction by Onconova Therapeutics Inc director. Derivative codes conversion of derivative security

Onconova Therapeutics Inc insider trading alert for conversion of series c convertible preferred stock by Michael Hoffman, the corporate stakeholder, on March 8, 2018. This event was filed by Onconova Therapeutics Inc with SEC on 2013-08-01. Statement of changes in beneficial ownership - SEC Form 4

Story Momentum

This media report from MacroaxisInsider distributed on March 8, 2018 was a factor to the next trading day price appreciation.The trading delta at closing time against the next closing price was 0.94% . The trading delta at closing time when the story was published against the current closing price is 50.94% .

Similar stores for Onconova Therapeutics

One Stock with Low Beta value Onconova Therapeuticsnews
Wallstreet InvestorplaceFull coverage
Dynamic volume-return relation of individual stocks Onconova Therapeutics, Inc., , The Coca-Cola ...news
Nyse Trading News Full coverage
over a week ago at http://postanalyst.com 
Onconova Therapeutics, Inc. held by 4 SEC 13F Filers
news
Post AnalystFull coverage
over two weeks ago at http://www.thestreetpoint.com 
Most latest Figure Make These Stocks Even More prominent Actinium Pharmaceuticals, Inc. , Onconova ...
Thestreet News
The Stock Street Full coverage
over two weeks ago at http://cardinalweekly.com 
American Express Company Trades at 105.98 After Triangle Onconova Therapeutics, Inc. Had 2 ...
news
The Cardinal Weekly Have You Holding This Low Risky Stock Onconova Therapeutics Wallstreet InvestorplaceNotable Stock to Watch Onconova Therapeutics NYSE WIRED Full coverage
over three weeks ago at http://dminute.com 
Sale by Michael Hoffman of 29999 shares of Onconova Therapeutics
news
Filed transaction by Onconova Therapeutics Inc director. General open market or private sale of non-derivative or derivative security
over a month ago at http://www.fairfieldcurrent.com 
Critical Analysis AC Immune versus Onconova Therapeutics
news
Fairfield CurrentTodd Asset Management Cut British Amern Tob Plc Adr Holding By 1.47 Million Onconova Therapeutics Position 2 Analysts Are Bullish Onconova ... The EN BulletinFull coverage
over a month ago at http://thewellesleysnews.com 
How Have Onconova Therapeutics, Inc. EPS Forecasts Changed
news
Analyst JournalEPS for Onconova Therapeutics, Inc. Expected At -0.08 Legal General Group Plc Has Upped Its Associated ... EN DigestFull coverage
over a month ago at http://www.thewellesleysnews.com 
Analyst Research Roundup Onconova Therapeutics, Inc. , Synthetic Biologics, Inc.
news
Analyst JournalFull coverage
over a month ago at http://www.thewellesleysnews.com 
Analyst Research and Recommendations Magellan Health, Inc. , Onconova Therapeutics, Inc.
news
Analyst JournalFull coverage
Onconova Therapeutics, Inc. Is this Stock Safe to Play innews
News Stays On Track Full coverage
over three months ago at http://stocksmarketcap.com 
Stocks Earnings Per Share to Watch Onconova Therapeutics Inc
news
Stocks Market CapFull coverage
over three months ago at http://stockspen.com 
Moving Averages Information in Focus Onconova Therapeutics Inc
news
Stocks PenOnconova Therapeutics, Inc. Reaches 0.87 52-Week Low Brandywine Realty Trust Has 1.54 Sentiment MTA StarFull coverage

Current Valuation

Current Valuation Comparative Analysis

  Current Valuation 
      Onconova Therapeutics Comparables 
Onconova Therapeutics is currently under evaluation in current valuation category among related companies. Enterprise Value is a firm valuation proxy that approximates current market value of a company. It is typically used to determine takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that company has on its balance sheet. When takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.

Peers

Onconova Therapeutics Related Equities

DRNA  2.06 %   
0%
44.0%
NK  1.64 %   
0%
35.0%
EARS  1.41 %   
0%
30.0%
DOVA  0.49 %   
0%
10.0%
CO  0.31 %   
6.0%
0%
DVAX  0.42 %   
8.0%
0%
ECYT  2.07 %   
44.0%
0%
DNLI  2.2 %   
47.0%
0%
EDGE  3.38 %   
72.0%
0%
DMPI  4.65 %   
100.0%
0%
Additionally take a look at Onconova Therapeutics Hype Analysis, Onconova Therapeutics Correlation and Onconova Therapeutics Performance. Please also try Chance of Distress module to get analysis of equity chance of financial distress in the next 2 years.
Search macroaxis.com